Member Info for Bmhltd

Final 1000 shares added at 164.9.

Ho, ho, ho, meeeeerry Christmas…! 🎅🏼🎄

All the best to you too Congas!

Dekkers will be, in parallel to the ongoing strategic deal making process, working a raise at a minimum of £2.50, which will encompass getting enough cash to both start the phase 2/3, possibly complete the first stage 40-40-40; plus retire the CLN, then weigh up whether it is worth doing the raise, if better partnering / full acquisition options are on the table; it’s the ultimate pressure move to improve bids for the company and / or other deals. I suspect we will be over £3 in 4-8 weeks maximum, and we may never see another dilution event from the CLN again, if there aren’t any advanced amortisation’s.

Dekkers is a world class CFO, pulling off moves such as the Acerta deal, a $7bn option to acquire with 4bn upfront from Astra Zeneca and a further $3 bn following approvals; he will be able to raise cash with strategic investors in weeks, and this is the play now as we move to fireside chats with institutional audiences in the US, it creates leverage for the deal making and gives us the ability to walk away which adds huge value in itself and also the option to move to the next stage with solid tumour combos also on the back burner.

The only issue is the stock price preventing us having a Forty Seven-esque valuation. The drug is far better even without hindsight due to the longevity and remarkable efficacy in the most difficult to treat TP-53 mutation burden population.

This is why Dekkers was brought in. And he is aligned with his 180k options. Now is the time to be looking over the horizon to the start of the pivotal trial and the hugely value adding solid time combination trials with a massively strengthened board, both financially and scientifically.

The talent is there, Dekkers will deliver, it’s what he does, and then true value can begin to emerge, be it slowly or faster if the deal making process gets lively. Now is the time to be buying if you believe in the asset- and it’s hard not to believe in the asset when it blew everything out of the water that came before it, whilst having an exemplary safety profile and opening a new frontier of immunotherapy, wholly owned by Faron.

Patience will pay here. And we are witnessing the changing of the guard in terms of share holders. A TR-1 or two may be likely in the coming weeks, as we have all the ingredients to make the piece d’resistance; we just have to sequence it correctly for a delicious billionaire short bread to come out of the oven at the correct time having been crafted by the experts currently in the kitchen…

Good luck all…

I’m not concerned Howard, but we must all do what’s best for ourselves, and always do our own research….!

Lol.

Just took another 494 to round up my earlier purchase too.

I figured I’d fill my stocking before xmas.

All the best.

Well, if I’m on the naughty list this year, its only right buy myself a present.

Added 1006 shares at 173.9.

See ya’ll next year…

Seasons greetings!

Https://ascopost.com/videos/ash-2025/tp53-mutated-higher-risk-mds-bexmarilimab-plus-azacitidine/

Looks as though we are getting the word out about Bexmarilimab, potentially leading to a premium high quality equity raise, which will strengthen our hand in the ongoing deal discussions.

Correct move, imo, if we are not yet seeing offers reflecting the intrinsic value of Faron.

I suspect the CLN and these types of moves will quickly flush out real value, but if not, then we march on as a standalone company and await for true value to be unearthed.

I think Juho has repeatedly played this well, and to give in to substandard offers / partnerships too soon would be a colossal error of judgement.

Big weeks coming up for the company, imo….

https://www.linkedin.com/posts/h%2Ec%2E-wainwright_register-today-to-attend-a-fireside-chat-activity-7405286792997793792-QclW?utm_medium=ios_app&rcm=ACoAADM1xY8BPFp_YBv8stSQEZalLsa87LNQA40&utm_source=social_share_send&utm_campaign=copy_link

Oh boo hoo hoooooooo…..!!!!!

You sound like you could be over leveraged, have you considered reducing a little so you don’t get overexcited?

🤣

Https://empoweredpatientradio.com/targeting-macrophages-instead-of-t-cells-to-overcome-treatment-resistant-cancers-with-dr-petri-bono-faron-pharmaceuticals

But thanks Itsa clearly my writing is considered first class…!

2/2

My view is that Gilead and Merck will move aggressively—they will not risk letting Clever-1 fall into a competitor’s hands. Others, including BMS, AbbVie, and Genentech, are also likely to be circling. Clever-1 and its soluble checkpoint variant are enormous biological discoveries, and whoever owns them effectively controls a new class of immunotherapy.

The only question is whether the offers emerging reflect this reality. If not, we continue building value and let the majors show who truly wants the whole cake—not a small slice of it.

1/2

Well that’s where you are completely wrong, but as you asked, here is chat GPT refining my passage, idioten, as they say in Germany…

There may still be some operational updates coming now that the second tranche of the HCM facility has been secured, although the extent of disclosure will naturally depend on the form and depth of the ongoing negotiations. Everything now hinges on whether incoming offers truly reflect the emerging scale of the bexmarilimab proposition.

While many of us would welcome a monster takeover today, I increasingly believe we should be shouting from the rooftops about our widening clinical horizon—particularly the planned PD-1 and chemotherapy combinations across melanoma, NSCLC, breast cancer, and soft-tissue sarcoma. After the latest ASH data, Faron is not a one-asset company; it is rapidly becoming a biology-defined oncology platform.

If we do not receive a valuation equivalent to (or greater than) the Forty Seven acquisition, we must be fully prepared to take this forward ourselves. Bexmarilimab’s profile is now indisputably broader, more durable, and significantly safer than Magrolimab ever demonstrated. We are seeing something Magrolimab never achieved: MRD negativity, stem-cell transplantation in both frontline and r/r TP53-mutated HR-MDS, and now transfusion independence—direct evidence that the marrow is not just clearing blasts but functionally recovering.

The arrival of Jurriaan Dekkers, combined with the second tranche bond, puts Faron in an exceptionally strong position. We now have optionality—ranging from a substantial premium equity raise that could make the CLN redundant, to selective partnerships, all the way to a full company sale. Dekkers’ background at Acerta is exactly the pedigree needed to extract maximum value.

Adjusted for inflation, the Forty Seven deal equates to roughly $6.5bn today. Given that bexmarilimab is safer, more efficacious, underpinned by deeper biology, and arguably more advanced in certain respects than Forty Seven was in 2020, anything materially below that level should not be entertained for a full acquisition. HR-MDS alone could justify 3–5x peak sales, and with a realistic peak of $8–10bn, paying that figure for the entire platform is not only plausible but financially compelling.

If the offers on the table today are not transformational, then the company should continue advancing the broader programme. Every new dataset—PD-1 combinations, solid tumours, soluble Clever-1 biology—expands the valuation envelope and forces big pharma to reassess. We need at least two deep-pocketed majors seriously in play, and the science now fully justifies it.

2/2

But then there are other potential partners such as BMS, Abbvie, and perhaps Genentech enter later in either scenario; but my current money is on a full acquisition, as the scope and scale of the discovery of Clever-1, soluble clever-1, and the IP rights to the checkpoint blockade of it, has potentially gargantuan value. And the returns just from HR-MDS, on a 3-5x peak sales basis, eg $10bn, make paying that figure highly plausible as a price tag, if that figure only ends up being a thin slither of the overall cake, which could be 10-20x bigger.

Everything considered, there is a chance the process runs on longer than some expect, in the meantime, I think we should be flashing some leg and cleavage through our upcoming trials if bids are not currently transformational and in line with previous macrophage targeted treatment acquisitions. Getting the big pharma boys excited about what we have and what’s to come, at least until we have a minimum of two deep pocketed majors, seriously in play and willing to pay full value, which may already be the case, if not, I’m happy to wait a little longer until the chips come down and we discover who has the biggest cojones…!

1/2

Perhaps a fair chance of some operational updates following securing the second tranche bonds, although that could be mitigated depending on what form the advanced negotiations are currently taking, and if we consider offers worthy of the existing scope of the bexmarilimab proposition.

Contrary to my own and others wanting of a monster takeover now, I think we should be singing from the roof tops about all our upcoming exciting clinical programmes ie combination trials with PD-1’s / chemo such as the melanoma, NSCLC, BC & STS trials, in light of the recent data presented at ASH

In my view, we must be willing to take this forwards ourselves if we do not see a Forty Seven style valuation. Our data is now more efficacious, more broad, has much greater longitudinal strength, and with a sublime safety profile, across both Bexmab & Matins, whilst treating the underlying aspects of disease, resulting in MRD negativity, Stem cell transplants and transfusion independence- that’s a serious differentiator and the holy grail compared to anything coming before it.

Following the appointment of Dekkers, and securing the second tranche bond, we are now in a superb position to raise funding at a significant premium to the current stock price & perhaps make the CLN entirely redundant, if the CFO sees fit, or to accompany the second tranche loan.

Furthermore, if we factor in inflation, a Forty Seven style valuation then, is worth around $6.5bn today, and bear in mind it is now irrefutably safer & more efficacious than Magrolimab was then, and easily arguably, at a more advanced point in its development and of higher calibre than Forty Seven was viewed as, in 2020.

I think to secure that mega valuation we should be firm about our intentions to take this forwards ourselves given the strong hand we have following the praise and recognition received from Bex data at all relevant major healthcare conferences, particularly the recent ASH data which I think has been overlooked and was a seminal moment for the company and Bexmarilimab, highlighting what we have here and how it can be utilised in even the toughest indications previously untouchable via an immuno oncology therapeutic.

So I know one in the hand can be worth two in the bush, but the one in the hand has to be a spectacular offer for the whole company, or it should involve us retaining a large share of the monster upside across other myeloid malignancies and solid tumours alike, if we are to go down the partnering route.

My view is the likes of Gilead and Merck will now be all over this company, and want the whole cake; and thus will be making their moves accordingly, that is to ensure a full takeover offer is more in SH’s interests than a smaller deal, cornering Juho and the board into selling out entirely.

Get what you can while you can, imho….!

HCM is highly incentivized to hold or even increase their position in the Second Tranche Bonds, essentially going “long” on Faron, because:

1. They get interest accrual while waiting.

2. They retain optionality to convert to shares if it’s profitable.

3. Cash payoff in a likely acquisition scenario is almost guaranteed.

Shorts getting smoked now, back over €2 in Helsinki and Faron can pay the whole thing off in cash, which I suspect is likely….

BOOM!

If we don’t get a fair deal now, we can get that premium raise in and march alone? But I suspect Merck and Gilead are going to go toe to toe here before long….

COME ONNNNNNN!!!!

📈

2.422 conversion price.

Was trading at 1.90 eur a few minutes ago, and I suspect Heights will be holding onto these.

Let’s see.

Fully strengthened into deal discussion- let’s GO!

Another 460 shares for me, cannot help myself at these levels…!